quadrivalent influenza vaccine (GSK)

This entry refers to a group of quadrivalent influenza vaccines (QIVs) utilized in clinical research, such as the study NCT04326166, to evaluate the immunological consequences of repeated annual vaccination. The group encompasses several distinct commercial products: **Fluarix Tetra** (GSK), **Vaxigrip Tetra** and **Fluquadri** (Sanofi), and three vaccines from CSL Seqirus: **Fluad Quad** (MF59-adjuvanted), **Afluria Quad** (standard inactivated), and **Flucelvax Quad** (cell-culture derived). These vaccines are designed to provide broad protection against four strains of the influenza virus, typically including two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). They function by inducing active immunity through the production of neutralizing antibodies against the viral hemagglutinin protein, thereby preventing infection and reducing disease severity.

Brand names

Afluria Quad

Other names

Afluia QuadQIVQuadrivalent inactivated influenza vaccine